Related Experiment Video
Updated: Jul 23, 2026
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
19.5K
Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement
A Iorio1,2, E Iserman1, V Blanchette3
1Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
Summary
Tailored prophylactic regimens using factor concentrate can improve quality of life for severe hemophilia patients. Expert consensus defined target plasma levels for personalized hemophilia treatment strategies.
Area of Science:
- Hematology
- Bleeding Disorders
Background:
- Prophylactic factor concentrate replacement is optimal for severe hemophilia, preventing bleeds and improving life expectancy.
- Optimal prophylactic regimens remain uncertain, driving interest in patient-tailored approaches.
- Personalized prophylaxis considers bleeding phenotype, activity levels, and other patient variables.
Purpose of the Study:
- To establish consensus-based target plasma levels for factor concentrate prophylaxis in hemophilia patients.
- To guide the development of patient-tailored treatment strategies.
Main Methods:
- A modified Delphi technique involving an expert panel was employed.
- Three iterative rounds were conducted to identify targets and scenarios.
- Consensus was sought on specific target plasma levels and treatment recommendations.
Main Results:
- Twenty-eight scenarios and eight target levels for factor concentrate were identified.
- The expert panel reached consensus on numerous positive and negative recommendations.
- Areas lacking consensus were highlighted for future research.
Conclusions:
- Expert consensus successfully generated target plasma levels for tailored hemophilia treatment.
- These targets aim to optimize prophylactic factor concentrate regimens for individual patients.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...